Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Age Related Macular Degeneration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    231 result(s) found for: Age Related Macular Degeneration. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-024001-12 Sponsor Protocol Number: LuMi-1 Start Date*: 2011-01-27
    Sponsor Name:TYKS
    Full Title: The effect of bevacizumab treatment on reading ability in age related macular degeneration
    Medical condition: Age related macular degeneration of the eye, wet form
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003766-17 Sponsor Protocol Number: 2007-06 Start Date*: 2007-12-06
    Sponsor Name:The Eye Hospital Rotterdam
    Full Title: Avastin-Injections in Age Related Macular Degeneration: Prospective Study for Optimal Frequency and Follow-up Determination
    Medical condition: Age-Related Macular Degeneration (ARMD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003763-22 Sponsor Protocol Number: BAY73-4506/15984 Start Date*: 2014-07-02
    Sponsor Name:Bayer HealthCare AG
    Full Title: A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age related macular degen...
    Medical condition: neovascular age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    18.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    18.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005500-18 Sponsor Protocol Number: VITCLEAR Start Date*: 2013-11-18
    Sponsor Name:King's College Hospital NHS Foundation Trust [...]
    1. King's College Hospital NHS Foundation Trust
    2. King's College London
    Full Title: A pharmacokinetic study: ranibizumab, aflibercept and the effect of vitrectomy
    Medical condition: Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    17.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017435-18 Sponsor Protocol Number: CLIN905 MLT202 Start Date*: 2010-02-04
    Sponsor Name:Steba Biotech S.A.
    Full Title: A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®)-Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects with Choroidal Neovasularization (CNV) Associated with Age-Rel...
    Medical condition: Age associated Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064930 Age-related macular degeneration LLT
    12.1 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024169-33 Sponsor Protocol Number: SPA/UIOS-AMD-1021 Start Date*: 2011-02-03
    Sponsor Name:Sucampo Pharma Americas, Inc.
    Full Title: A Single-center, Double-masked, Randomized, Pharmacodynamic Crossover Study of Ocular Blood Flow Effects of Topically-administered Unoprostone in Adults with Age-related Macular Degeneration (AMD)
    Medical condition: Age related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004540-36 Sponsor Protocol Number: 1076/08 Start Date*: 2009-03-01
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Effetto della supplementazione dietetica con estratto di Crocus sativus (zafferano) sulla funzione retinica maculare nella degenerazione maculare legata all’eta’ (AMD) in fase iniziale (Protocollo ...
    Medical condition: Age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025410 Macular degeneration (senile) of retina, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006312-30 Sponsor Protocol Number: MACPED-06-01 Start Date*: 2007-04-05
    Sponsor Name:Dept. of Ophthalmol, Semmelweis University
    Full Title: A phase IV non-randomized, uncontrolled, open-label, single-center trial to evaluate the safety and efficacy of Macugen (pegaptanib sodium) given by intravitreal injections every 6 weeks in patient...
    Medical condition: neovascular (wet) age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021777-37 Sponsor Protocol Number: Lucentis-LucERG Start Date*: 2010-09-27
    Sponsor Name:Universitätsklinikum Schleswig-Holstein (UK-SH)
    Full Title: "A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with we...
    Medical condition: Retinal function in patients with wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005174-94 Sponsor Protocol Number: ISIS696844-CS5 Start Date*: 2021-08-18
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geogr...
    Medical condition: Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    20.1 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) NL (Completed) ES (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004675-22 Sponsor Protocol Number: ADM-PED08 Start Date*: 2008-10-21
    Sponsor Name:University of Bonn
    Full Title: Intravitreal ranibizumab in patients with retinal pigment epithelial detachments secondary to AMD
    Medical condition: Pigment epithelial detachments secondary to age-relatedmacular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005807-33 Sponsor Protocol Number: Version_V3_0 Start Date*: 2013-01-31
    Sponsor Name:Medizinische Fakultät der Universität Bonn
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender:
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015681-55 Sponsor Protocol Number: C-09-023 Start Date*: 2010-03-18
    Sponsor Name:Alcon Research, Ltd.
    Full Title: A Dose-Escalation Study of AL-39324 Suspension versus Lucentis™ for the Treatment of Exudative Age-Related Macular Degeneration
    Medical condition: Exudative Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    14.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002101-39 Sponsor Protocol Number: MD7111396 Start Date*: 2008-09-25
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascolar age-related macular degeneration
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025409 Macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004078-24 Sponsor Protocol Number: TAPAS Start Date*: 2013-01-24
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: Intravitreal Tissue Plasminogen Activator (tPA), Perfluoropropane (C3F8), and Ranibizumab for Neovascular Age-Related Macular Degeneration and Submacular Haemorrhage (TAPAS): A Randomized, Double-M...
    Medical condition: Sub-macular haemorrhage secondary to wet macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    16.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    16.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003204-12 Sponsor Protocol Number: ICI21/00025 Start Date*: 2022-03-16
    Sponsor Name:Consorcio PSMAR
    Full Title: Multicentre, randomised, double-blind, parallel-group, Phase III study to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age-...
    Medical condition: age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-006014-18 Sponsor Protocol Number: 1419 Start Date*: 2005-12-15
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Macular structure and function after intravitreal injection of bevacizumab for wet macular degeneration a interventional study.
    Medical condition: Macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002526-43 Sponsor Protocol Number: 150998-001 Start Date*: 2012-01-30
    Sponsor Name:Allergan Limited
    Full Title: Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration
    Medical condition: Exudative Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004487-53 Sponsor Protocol Number: 2312/2007 Start Date*: 2007-12-13
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Pilot study of association of VEGF polymorphisms with clinical efficacy and tolerability of therapy in patients affected by exudative (neovascular) age-related macular degeneration.
    Medical condition: Exudative and atrophic age-related macular degeneration.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018741-65 Sponsor Protocol Number: OPH1001A Start Date*: 2010-04-21
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS INJECTIONS OF E10030 (ANTI-PDGF PEGYLATED APTAMER) GIVEN IN COMBINATION WITH LUCENTIS® I...
    Medical condition: Subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    14.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) FR (Completed) BE (Completed) DE (Completed) ES (Completed) HU (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:21:01 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA